Annual SG&A
$25.68 M
+$1.40 M+5.75%
31 December 2023
Summary:
Silence Therapeutics annual selling, general & administrative expenses is currently $25.68 million, with the most recent change of +$1.40 million (+5.75%) on 31 December 2023. During the last 3 years, it has risen by +$7.73 million (+43.08%). SLN annual SG&A is now -6.71% below its all-time high of $27.53 million, reached on 31 December 2021.SLN Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$7.29 M
+$615.10 K+9.22%
01 September 2024
Summary:
Silence Therapeutics quarterly selling, general & administrative expenses is currently $7.29 million, with the most recent change of +$615.10 thousand (+9.22%) on 01 September 2024. Over the past year, it has increased by +$1.01 million (+16.11%). SLN quarterly SG&A is now -10.30% below its all-time high of $8.12 million, reached on 31 December 2020.SLN Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.64 B
-$109.32 M-7.13%
01 September 2024
Summary:
Silence Therapeutics TTM selling, general & administrative expenses is currently -$1.64 billion, with the most recent change of -$109.32 million (-7.13%) on 01 September 2024. Over the past year, it has dropped by -$1.67 billion (-6779.20%). SLN TTM SG&A is now -6873.03% below its all-time high of $30.09 million, reached on 31 March 2022.SLN TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SLN Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.8% | +16.1% | -6779.2% |
| 3 y3 years | +43.1% | -3.4% | -5894.3% |
| 5 y5 years | +77.7% | - | - |
SLN Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -6.7% | +43.1% | -7.0% | +78.7% | -100.4% | at low |
| 5 y | 5 years | -6.7% | +108.6% | -10.3% | +111.5% | -334.2% | at low |
| alltime | all time | -6.7% | >+9999.0% | -10.3% | +111.5% | -6873.0% | at low |
Silence Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $7.29 M(+9.2%) | $25.63 M(+4.1%) |
| June 2024 | - | $6.67 M(+1.7%) | $24.62 M(+1.1%) |
| Mar 2024 | - | $6.56 M(+28.3%) | $24.35 M(-5.0%) |
| Dec 2023 | $25.68 M(+5.7%) | $5.11 M(-18.6%) | $25.63 M(+4.2%) |
| Sept 2023 | - | $6.28 M(-2.0%) | $24.60 M(-2.3%) |
| June 2023 | - | $6.40 M(-18.3%) | $25.18 M(+2.8%) |
| Mar 2023 | - | $7.84 M(+92.3%) | $24.49 M(+0.4%) |
| Dec 2022 | $24.28 M(-11.8%) | $4.08 M(-40.5%) | $24.39 M(-11.7%) |
| Sept 2022 | - | $6.86 M(+19.9%) | $27.61 M(-2.4%) |
| June 2022 | - | $5.72 M(-26.1%) | $28.29 M(-6.0%) |
| Mar 2022 | - | $7.74 M(+6.1%) | $30.09 M(+9.3%) |
| Dec 2021 | $27.53 M(+53.4%) | $7.29 M(-3.3%) | $27.52 M(-2.9%) |
| Sept 2021 | - | $7.54 M(+0.4%) | $28.35 M(+16.9%) |
| June 2021 | - | $7.52 M(+45.4%) | $24.25 M(+44.9%) |
| Mar 2021 | - | $5.17 M(-36.4%) | $16.74 M(+44.7%) |
| Dec 2020 | $17.95 M(+45.8%) | $8.12 M(+135.8%) | $11.57 M(+235.8%) |
| Sept 2020 | - | $3.45 M | $3.45 M |
| Dec 2019 | $12.31 M(-14.8%) | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $14.45 M(+73.1%) | - | - |
| Dec 2017 | $8.35 M(+55.4%) | - | - |
| Dec 2016 | $5.37 M(+32.4%) | - | - |
| Dec 2015 | $4.06 M(-24.4%) | - | - |
| Dec 2014 | $5.37 M(-3.1%) | - | - |
| Dec 2013 | $5.54 M(+33.8%) | - | - |
| Dec 2012 | $4.14 M(-2.4%) | - | - |
| Dec 2011 | $4.24 M(+404.3%) | - | - |
| Dec 2010 | $841.70 K(+81.6%) | - | - |
| Dec 2009 | $463.60 K(+78.2%) | - | - |
| Dec 2007 | $260.20 K(-18.9%) | - | - |
| Dec 2006 | $320.80 K(+1.3%) | - | - |
| Dec 2005 | $316.60 K(-72.1%) | - | - |
| Dec 2004 | $1.14 M(+260.1%) | - | - |
| Dec 2003 | $315.60 K(+69.3%) | - | - |
| Dec 2002 | $186.40 K(+33.4%) | - | - |
| Dec 2001 | $139.70 K(+16.7%) | - | - |
| Dec 2000 | $119.70 K | - | - |
FAQ
- What is Silence Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Silence Therapeutics?
- What is Silence Therapeutics annual SG&A year-on-year change?
- What is Silence Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Silence Therapeutics?
- What is Silence Therapeutics quarterly SG&A year-on-year change?
- What is Silence Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Silence Therapeutics?
- What is Silence Therapeutics TTM SG&A year-on-year change?
What is Silence Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of SLN is $25.68 M
What is the all time high annual SG&A for Silence Therapeutics?
Silence Therapeutics all-time high annual selling, general & administrative expenses is $27.53 M
What is Silence Therapeutics annual SG&A year-on-year change?
Over the past year, SLN annual selling, general & administrative expenses has changed by +$1.40 M (+5.75%)
What is Silence Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of SLN is $7.29 M
What is the all time high quarterly SG&A for Silence Therapeutics?
Silence Therapeutics all-time high quarterly selling, general & administrative expenses is $8.12 M
What is Silence Therapeutics quarterly SG&A year-on-year change?
Over the past year, SLN quarterly selling, general & administrative expenses has changed by +$1.01 M (+16.11%)
What is Silence Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of SLN is -$1.64 B
What is the all time high TTM SG&A for Silence Therapeutics?
Silence Therapeutics all-time high TTM selling, general & administrative expenses is $30.09 M
What is Silence Therapeutics TTM SG&A year-on-year change?
Over the past year, SLN TTM selling, general & administrative expenses has changed by -$1.67 B (-6779.20%)